High growth and order backlog support an optimistic view; Singapore capacity ramp-up and commercial contract conversion are the next key factors

Overview

This report summarizes key takeaways from WuXi XDC's 1H26 non-deal roadshow, focusing on earnings growth, long-term revenue targets, order backlog, ADC commercial manufacturing capacity supply and demand, the Singapore site's impact on margins, and capital expenditure plans. Morgan Stanley's core assessment is positive, although the conversion of commercial contracts and utilization of new capacity remain key variables affecting growth quality and margins.

Core views

First, operating growth remained strong in 1H26: revenue increased 37.0% year over year, and adjusted net profit increased 37.4% year over year. Management's standalone constant-exchange-rate revenue growth guidance is 35%, or approximately 40% including BioDlink; BioDlink contributed approximately 3.9% of total revenue in 1H26. The company also maintained its five-year guidance for a 30%–35% revenue CAGR from 2025 to 2030 and plans for manufacturing to contribute 20% of total revenue by 2030. This means the growth thesis depends not only on research-stage services but also on revenue scaling as more projects advance to later stages and commercial manufacturing. Orders and industry capacity supply-demand dynamics provide important support for medium-term growth visibility. Total order backlog reached US$2.2 billion in 1H26, up 62.2% year over year, while service order backlog reached US$2.0 billion, up 50.4% year over year. However, the company included commercial orders and milestone payments in total backlog for the first time, so changes in the scope of measurement should be considered when comparing growth rates. Management believes that despite continued industry capital expenditure, commercial-scale ADC manufacturing capacity could still face a supply shortage over the next 2–3 years. If late-stage projects advance faster and blockbuster products are successfully launched, demand for commercial manufacturing capacity could rise further. Following its first AIDD transaction, the company signed another licensing transaction with a European biotechnology company, with details expected to be announced later, which will further increase the IP revenue backlog. Regarding margins, the company expects gross margin to remain stable relative to 2025, but the Singapore site is the main uncertainty. Under a low-utilization assumption, the site could dilute overall gross margin by up to 2 percentage points in 2027. Utilization is expected to ramp slowly because most products associated with biologics license applications will initially continue to be manufactured at the Wuxi site after launch. High utilization and continued operating leverage at the Wuxi site could partially offset the impact of the Singapore site. Conversely, if utilization at the Singapore site rises faster than expected, its gross margin improvement could also accelerate. Regarding capacity expansion, the company plans capital expenditure of Rmb8.0 through 2030, although the original text does not further specify the unit of scale. The spending will primarily fund construction of the Jiangyin site and overseas expansion, with 60%–70% expected to be invested before 2028. In addition to building capacity internally, the company is also evaluating potential capability additions through M&A, such as acquiring a small European CDMO. This arrangement could help address a potential shortage of commercial manufacturing capacity, but it also makes the pace of capital deployment, new-capacity ramp-up, and integration execution important factors to monitor. Morgan Stanley's model forecasts net revenue increasing from Rmb5.944 billion in 2025 to an estimated Rmb8.150 billion in 2026, Rmb11.059 billion in 2027, and Rmb14.869 billion in 2028. Over the same period, EBITDA is projected to rise from Rmb1.803 billion to Rmb2.478 billion, Rmb3.460 billion, and Rmb4.830 billion, while ModelWare net profit is projected to increase from Rmb1.559 billion to Rmb2.086 billion, Rmb3.058 billion, and Rmb4.128 billion. The corresponding P/E declines from 46.4x in 2025 to an estimated 22.0x in 2028, while EV/EBITDA declines from 33.4x to 14.6x, reflecting the model's projected earnings growth absorbing the valuation multiples. The target price is derived using a DCF methodology, assuming a 10% WACC, a 5% perpetual growth rate, and an HKD/RMB exchange rate of 0.92, resulting in HK$85.00. Relative to the August 26, 2026 closing price of HK$77.25, this implies 10% upside. The target-price history shows an increase from HK$80 on July 3, 2026 to HK$85 on August 25, but the report does not explicitly state that the stock rating changed.

Analysis framework

The report first uses 1H26 results and management's roadshow discussions to confirm the current growth trajectory, then assesses growth visibility through long-term revenue guidance, the target manufacturing revenue contribution, order backlog, and ADC commercial manufacturing capacity supply-demand dynamics. It subsequently evaluates the impact of the Singapore site's ramp-up on gross margin and analyzes the company's ability to accommodate capacity demand in conjunction with capital expenditure plans for Jiangyin and overseas expansion. Financial forecasts are primarily based on Morgan Stanley ModelWare, while the target price uses a DCF methodology consistent with that applied to other CDMO companies, converting medium- to long-term cash flows into equity value through assumptions for WACC, perpetual growth, and exchange rates.

Methodology notes

• Valuation MethodologyDCF Discounted Cash Flow

  DCF Valuation

  The report discounts the company's future cash flows to present value, using a 10% WACC as the discount rate, a 5% perpetual growth rate, and an assumed HKD/RMB exchange rate of 0.92, resulting in a target price of HK$85.00.

• Industry/Sector Analysis FrameworkSupply-demand framework

  Assessment of ADC Commercial Manufacturing Capacity Supply and Demand

  The report compares capacity demand arising from the advancement of late-stage projects and product commercialization with industry capital expenditure and existing commercial-scale ADC manufacturing capacity, concluding that a capacity shortage could emerge over the next 2–3 years.

• Company Fundamentals and Financial Framework

  Morgan Stanley ModelWare Forecasting Framework

  The report uses Morgan Stanley ModelWare to generate forecasts for revenue, EBITDA, net profit, and valuation multiples, while using market consensus estimates provided by Refinitiv Estimates as a comparison basis for certain metrics.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi XDC Cayman Inc. (2268.HK)

  The report believes the company could benefit from an increasing number of ADC projects, the advancement of late-stage projects, commercial product launches, and tightening industry capacity.

  Strengths

  Both revenue and adjusted net profit increased by approximately 37% in 1H26, total order backlog and service order backlog reached US$2.2 billion and US$2.0 billion, respectively, and the company maintained its guidance for a 30%–35% revenue CAGR from 2025 to 2030.

  Weaknesses

  Utilization at the Singapore site is expected to ramp slowly and could dilute gross margin by up to 2 percentage points in 2027 under a low-utilization scenario; most BLA-related products will initially continue to be manufactured at the Wuxi site.

  Comparison

  The report states that its DCF valuation methodology is consistent with that used for other CDMO companies, but it does not provide operating or valuation comparisons with specific companies.

  Risks

  Slower biotechnology financing and pipeline advancement, lower-than-expected sales from late-stage and commercial contracts, weaker-than-expected gross margin improvement at new facilities, and slower execution of new-capacity construction or integration.

Key data

• 1H26 Revenue GrowthUp 37.0% year over yearThe company's first-half operating growth
• 1H26 Adjusted Net Profit GrowthUp 37.4% year over yearBroadly in line with revenue growth
• Revenue Growth Guidance35% standalone CER growth; approximately 40% including BioDlinkBioDlink contributed approximately 3.9% of total revenue in 1H26
• Five-Year Revenue Guidance2025–2030 CAGR of 30%–35%The company maintained its existing long-term growth target
• Manufacturing Business Target20% of revenue by 2030Reflects an extension of the revenue mix toward commercial manufacturing
• Total Order BacklogUS$2.2 billionUp 62.2% year over year in 1H26, with commercial orders and milestone payments included for the first time
• Service Order BacklogUS$2.0 billionUp 50.4% year over year in 1H26
• ADC Capacity Supply-Demand AssessmentPotential shortage over the next 2–3 yearsRefers to commercial-scale ADC manufacturing capacity, despite continued industry capital expenditure
• Singapore Site Gross Margin ImpactUp to 2 percentage points of dilution in 2027Based on a low-utilization assumption; high utilization and operating leverage at the Wuxi site could partially offset the impact
• Capital Expenditure PlanRmb8.0 through 2030The original text does not specify the unit of scale; primarily for the Jiangyin site and overseas expansion, with 60%–70% planned for investment before 2028
• Net Revenue Forecast2025/2026e/2027e/2028e: Rmb5,944mn/8,150mn/11,059mn/14,869mnMorgan Stanley ModelWare forecast
• EBITDA Forecast2025/2026e/2027e/2028e: Rmb1,803mn/2,478mn/3,460mn/4,830mnCorresponds to continued earnings expansion
• ModelWare Net Profit Forecast2025/2026e/2027e/2028e: Rmb1,559mn/2,086mn/3,058mn/4,128mnNet profit under the model's methodology
• Earnings per Share Forecast2025/2026e/2027e/2028e: Rmb1.18/1.52/2.23/3.01Morgan Stanley figures as stated in the report; consensus estimates are Rmb1.27/1.53/2.20/2.86, respectively
• Valuation MultiplesP/E: 46.4/43.5/29.7/22.0x; EV/EBITDA: 33.4/30.4/21.3/14.6xCorresponding to 2025, 2026e, 2027e, and 2028e, respectively
• Key DCF AssumptionsWACC 10%; perpetual growth rate 5%; HKD/RMB 0.92Used to calculate the base-case target price
• Rating and Target PriceOverweight; HK$85.00Industry view is Attractive, implying 10% upside from the HK$77.25 closing price
• Latest Target Price ChangeHK$80 (July 3, 2026) increased to HK$85 (August 25, 2026)The report does not explicitly state a stock rating change

Impact & implications

The report believes that rapidly growing order backlog, projects advancing toward late-stage and commercial phases, and a potential shortage of ADC commercial manufacturing capacity over the next 2–3 years collectively support the company's medium-term revenue growth and an increased manufacturing revenue contribution. At the same time, new capacity will not immediately translate into profits: low initial utilization at the Singapore site could depress gross margin in 2027, while concentrated capital expenditure also requires the company to effectively ramp capacity, convert orders, and integrate potential acquisitions. The DCF target price reflects the report's confidence in medium- to long-term growth, but it also depends on the realization of the 10% WACC, 5% perpetual growth rate, and operating forecasts.

Risks

• Upside risk: Order growth across all stages of drug development is faster than expected.
• Upside risk: Late-stage projects ramp rapidly and successfully launch blockbuster products.
• Upside risk: Utilization at the Singapore site rises rapidly, driving faster-than-expected gross margin improvement.
• Downside risk: Biotechnology financing and R&D pipeline advancement slow.
• Downside risk: Sales revenue generated from late-stage and commercial contracts is lower than expected.
• Downside risk: Gross margin improvement at new facilities is lower than expected.

What to watch

• Monitor the utilization ramp-up at the Singapore site and its actual impact on gross margin in 2027.
• Monitor whether late-stage projects and commercial contracts convert into sales revenue as expected.
• Monitor whether commercial-scale ADC manufacturing capacity experiences a shortage over the next 2–3 years as management expects.
• Monitor the specific terms of the new AIDD licensing transaction with a European biotechnology company and its contribution to IP revenue.
• Monitor the conversion of order backlog into revenue and the comparability of the measurement scope after including commercial orders and milestone payments.
• Monitor the investment progress and execution of the Jiangyin site, overseas expansion, and potential acquisition of a European CDMO.